



Scan this QR code to view Prospectus

# CURIS LIFESCIENCES LIMITED

CIN: U24230GJ2016PLC086559

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "M/s Loreto Pharmaceuticals", pursuant to a deed of partnership dated June 2, 2010. Thereafter "M/s Loreto Pharmaceuticals" was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of "Curis Lifesciences Private Limited" and received a certificate of incorporation dated March 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from "Curis Lifesciences Private Limited" to "Curis Lifesciences Limited" vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/Deputy Registrar of Companies/Registrar of Companies, Central Processing Centre.

Registered Office: PF-23, GIDC Sanand - II, Industrial Estate, Ahmedabad, Sanand, Gujarat -382110, India.

Company Secretary and Compliance Officer: Mr. Nikhil Purohit

Website: <https://curisls.com/> E-Mail: [cs@curisls.com](mailto:cs@curisls.com) Telephone No: +91 99045 22543

## PROMOTERS OF OUR COMPANY: MR. DHARMESH DASHARATHBHAI PATEL, MR. SIDDHANT JAYANTIBHAI PAWASIA, MR. PIYUSH GORDHANBHAI ANTALA AND MR. JAIMIK MANSUKHLAL PATEL

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON EMERGE PLATFORM OF NSE ("NSE EMERGE")."

Curis Lifesciences is the pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral Liquid, Sterile Ophthalmic Ointments. We are in business of manufacturing of pharmaceutical products.

For further details, please see chapter titled "Business Overview" beginning on page 133 of the Prospectus.

## BASIS OF ALLOTMENT CUM CORRIGENDUM

INITIAL PUBLIC ISSUE OF 21,50,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF CURIS LIFESCIENCES LIMITED ("CURIS" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 2752.00 LAKHS ("THE ISSUE"), OF WHICH 1,08,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE AGGREGATING TO ₹ 138.24 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 20,42,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 128/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 118/- PER EQUITY SHARE AGGREGATING TO ₹ 2613.76 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.59% AND 25.26%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

**THE FACE VALUE OF THE EQUITY SHARE IS ₹ 10 EACH AND ISSUE PRICE IS ₹ 128 EACH**

**THE ISSUE PRICE IS 12.80 TIMES OF THE FACE VALUE OF THE EQUITY SHARE.**

**ANCHOR INVESTOR ISSUE PRICE: ₹ 128 PER EQUITY SHARE. THE ISSUE PRICE IS 12.80 TIMES OF THE FACE VALUE.**

## BID/ISSUE PROGRAMME

**ANCHOR INVESTOR BIDDING DATE WAS: NOVEMBER 6, 2025, THURSDAY**

**BID/ISSUE OPENED ON: NOVEMBER 7, 2025, FRIDAY**

**BID/ISSUE CLOSED ON: NOVEMBER 11, 2025, TUESDAY**

## RISKS TO INVESTORS

Summary description of key risk factors based on materiality

- Our manufacturing facility is concentrated in Sanand, Ahmedabad, Gujarat, exposing us to risks from economic, regulatory, political, and other regional changes, including natural disasters, which could negatively impact our business operations, financial performance, and overall condition.
- As a pharmaceutical company, we operate in a highly regulated industry where our business relies on obtaining approvals from relevant regulatory and health authorities. Delays or failures in securing or renewing these essential approvals, registrations, or changes in the regulatory environment for marketing our products in regulated markets could have a significant impact on our business and strategy, ultimately affecting our overall profitability.
- Our business operations are subject to fluctuations in raw material prices.
- Any non-compliance or delays in Instalments of Outstanding loan may expose us to penalties from the Bank.
- The company relies on a limited number of customers for its sales, and the loss of any major customer could adversely impact our revenue and profitability.
- The company relies on a limited number of suppliers for product procurement, and the loss of any key supplier could impact our business operations.
- We depend on a limited number of States for a significant portion of our revenue from operations. The loss of any of our major customer in these States due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.
- Our Company is dependent on few countries. Loss of any of these large countries may affect our business operations.
- A disclosure remark on compliance of Companies (Auditor's Report) Order, 2020 towards non payment of statutory dues in financial year ended March 31, 2020, March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024 have been noted by our Statutory Auditors in their reports.
- Our Company depends on some of our Products which contributes more than 90% of the total revenue of the company. The loss of any of this major Products due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.

For details refer to chapter titled "Risk Factors" beginning on page 25 of the Prospectus.

1. The Average Cost of acquisition of Equity Shares held by our Promoters is as follows:

Sr. No.	Name	No. of Equity Shares	Average cost of acquisition per Equity Share (in ₹)
1	Dharmesh Dashrathbhai Patel	10,72,500	0.91
2	Siddhant Jayantibhai Pawasia	15,40,000	0.91
3	Piyush Gordhanbhai Antala	12,65,000	0.91
4	Jaimik Mansukhlal Patel	8,80,000	0.85

and the Issue Price at the upper end of the Price Band is ₹ 128/- Per Equity Share.

- The Price/ Earnings ratio based on Diluted EPS for Fiscal 2025 for the company at the upper end of the Price Band is 12.44.
- Weighted Average Return on Net worth for Fiscals 2025, 2024, and 2023 is 77.51%.
- The Weighted average cost of acquisition of all Equity Shares transacted in the last one year, 18 months and three years from the date of Prospectus is as given below:

Period	Weighted Average Cost of Acquisition	Upper Band of the Price Band is (₹ 128/-) is "X" times the Weighted Average cost of Acquisition	Range of acquisition price: Lowest Price - Highest Price (In ₹)
Last 1 year	Nil	Nil	Nil
Last 18 months	7.82	16.37	0-1076
Last 3 years	7.81	16.39	0-1076

5. The Weighted average cost of acquisition (WACA) compared to floor price and cap price

Types of transactions	Weighted average cost of acquisition (₹ per Equity Shares)	Floor price (i.e. ₹ 120)	Cap price (i.e. ₹ 128)
Weighted average cost of acquisition for last 18 months for primary / new issue of shares (equity / convertible securities), excluding shares issued under an employee stock option plan/employee stock option scheme and issuance of bonus shares, during the 18 months preceding the date of filing of the Prospectus, where such issuance is equal to or more than five per cent of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options), in a single transaction or multiple transactions combined together over a span of rolling 30 days	7.82	15.35	16.37
Weighted average cost of acquisition for last 18 months for secondary sale / acquisition of shares equity / convertible securities), where promoter / promoter group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) in our Board are a party to the transaction (excluding gifts), during the 18 months preceding the date of filing of the Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid-up share capital of our Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days	N.A.	N.A.	N.A.
Since there were no secondary transactions of equity shares of our Company during the 18 months preceding the date of filing of the Prospectus, which are equal to or more than 5% of the fully diluted paid-up share capital of our Company, the information has been disclosed for price per share of our Company based on the last five secondary transactions where promoter / promoter group entities or Selling Shareholder or shareholder(s) having the right to nominate director(s) on our Board, are a party to the transaction, not older than three years prior to the date of filing of the Prospectus irrespective of the size of the transaction.	N.A.	N.A.	N.A.

## PROPOSED LISTING: NOVEMBER 14, 2025\*

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Issue Price. In terms of Regulation 256 of SEBI ICDR Regulations read with SEBI Circular No. CIR/CFD/POLICYCELL/11/2015, dated November 10, 2015 and Unified Payments Interface (UPI) introduced vide SEBI Circular Ref: SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, all Bidders are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Issue Procedure" beginning on page 325 of Prospectus.

The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to NSE. For the purpose of this Issue, the designated Stock Exchange will be the National Stock Exchange of India Limited. The trading is proposed to be commenced on or before November 14, 2025\*

\*Subject to the receipt of listing and trading approval from the ("NSE EMERGE").

## SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on November 06, 2025. The Company received 06 Anchor Investor Application Forms from 06 Anchor Investors for 9,45,000 Equity Shares. Such 06 Anchor Investors through 06 Anchor Investor Application Forms were allocated 6,09,000 Equity Shares at a price of ₹128 per Equity Share under the Anchor Investor Portion, aggregating to ₹ 7,79,52,000/-.

The Issue (excluding Anchor Investors Portion) received 21,539 Applications for 10,69,31,000 Equity Shares (before rejections) resulting in 69.3907 times subscription (including reserved portion of market maker). The details of the Applications received in the Issue from various categories are as under (before rejections):

Detail of the Applications Received (excluding Anchor Investors Portion):

SR NO	CATEGORY	NO OF APPL	NO OF SHARES	RESERVED	NO OF TIMES SUBSCRIPTION	AMOUNT
1	MARKET MAKER	1	1,08,000	1,08,000	1.0000	1,38,24,000.00
2	QIB	43	3,93,32,000	4,08,000	96.4020	5,03,44,96,000.00
3	HNI UPTO 10 LAC	1,985	62,04,000	1,02,000	60.8235	79,39,76,000.00
4	HNI ABOVE 10 LAC	3,613	2,94,93,000	2,07,000	142.4783	3,77,51,04,000.00
5	INDIVIDUAL INVESTOR	15,897	3,17,94,000	7,16,000	44.4050	4,06,87,58,000.00
	<b>TOTAL</b>	<b>21,539</b>	<b>10,69,31,000</b>	<b>15,41,000</b>	<b>69.3907</b>	<b>13,68,61,58,000.00</b>

Final Demand:

A summary of the final demand as per NSE as on the Bid/ Offer Closing Date at different Bid prices is as under:

SR NO	RATE	SHARES	% TO TOTAL	CUMULATIVE TOTAL	CUMULATIVE % TO TOTAL
1	120	2,01,000	0.17	2,01,000	0.17
2	121	16,000	0.01	2,17,000	0.19
3	122	10,000	0.01	2,27,000	0.19
4	123	4,000	0.00	2,31,000	0.20
5	125	48,000	0.04	2,79,000	0.24
6	126	26,000	0.02	3,05,000	0.26
7	127	20,000	0.02	3,25,000	0.28
8	128	11,61,01,000	99.72	11,64,26,000	100.00
	<b>TOTAL</b>	<b>11,64,26,000</b>	<b>100.00</b>		

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being National Stock Exchange of India Limited on November 12, 2025.

1) Allotment to Individual Investors who applies for minimum who applies for minimum application size (After Rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 44.0223 times for 3,15,20,000 Equity Shares. Total number of shares allotted in this category is 7,16,000 Equity Shares to 358 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	2000	15,760	100.00	3,15,20,000	100.00	2000	1:44	7,16,000
	<b>TOTAL</b>	<b>15,760</b>	<b>100.00</b>	<b>3,15,20,000</b>	<b>100.00</b>			<b>7,16,000</b>

2) Allotment to Non-Institutional Investors (More than 2 lots and up to ₹ 1,00,00,000) (After Rejections):

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 60.2451 times (after rejection) for 61,45,000 Equity Shares. Total number of shares allotted in this category is 1,02,00,000 Equity Shares to 34 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	3,000	1865	94.72	55,95,000	91.05	3,000	32:1865	96,000
2	5,000	37	1.88	1,85,000	3.01	3,000	1:37	3,000
3	4,000	28	1.42	1,12,000	1.82	3,000	0:28	0
4	6,000	20	1.02	1,20,000	1.95	3,000	0:20	0
5	7,000	19	0.96	1,33,000	2.16	3,000	0:19	0
6	0	All applicants from Serial no 03 to 05 for 1 (one) lot of 3000 shares				3,000	1:67	3,000
	<b>TOTAL</b>	<b>1969</b>	<b>100.00</b>	<b>61,45,000</b>	<b>100.00</b>			<b>102,000</b>

**3) Allotment to Non-Institutional Investors (More than ₹ 1,000,000) (After Rejections):**

The Basis of Allotment to the Non-Institutional Investors, who have bid at cut-off Price or at or above the Issue Price of ₹ 128/- per Equity Share, was finalized in consultation with NSE. The category has been subscribed to the extent of 142.0483 times for 2,94,04,000 Equity Shares. Total number of shares allotted in this category is 2,07,000 Equity Shares to 69 successful applicants. The details of the Basis of Allotment of the said category are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	8,000	3527	97.86	2,82,16,000	95.96	3,000	68:3527	2,04,000
2	9,000	25	0.69	2,25,000	0.77	3,000	0:25	0
3	10,000	19	0.53	1,90,000	0.65	3,000	0:19	0
4	11,000	4	0.11	44,000	0.15	3,000	0:4	0
5	12,000	7	0.19	84,000	0.29	3,000	0:7	0
6	13,000	1	0.03	13,000	0.04	3,000	0:1	0
7	15,000	2	0.06	30,000	0.10	3,000	0:2	0
8	16,000	4	0.11	64,000	0.22	3,000	0:4	0
9	20,000	1	0.03	20,000	0.07	3,000	0:1	0
10	21,000	4	0.11	84,000	0.29	3,000	0:4	0
11	23,000	1	0.03	23,000	0.08	3,000	0:1	0
12	29,000	1	0.03	29,000	0.10	3,000	0:1	0
13	30,000	1	0.03	30,000	0.10	3,000	0:1	0
14	32,000	2	0.06	64,000	0.22	3,000	0:2	0
15	41,000	1	0.03	41,000	0.14	3,000	0:1	0
16	42,000	1	0.03	42,000	0.14	3,000	0:1	0
17	66,000	1	0.03	66,000	0.22	3,000	0:1	0
18	67,000	1	0.03	67,000	0.23	3,000	0:1	0
19	72,000	1	0.03	72,000	0.24	3,000	0:1	0
20	0	All applicants from Serial no 02 to 19 for 1 (one) lot of 3000 shares				3,000	1:77	3,000
	<b>TOTAL</b>	<b>3604</b>	<b>100.00</b>	<b>29404000</b>	<b>100.00</b>			<b>207000</b>

**4) Allotment to QIBs excluding Anchor Investors (After Rejections):**

Allotment to QIBs, who have bid at the Issue Price of ₹ 128/- per Equity Share or above, has been done on a proportionate basis in consultation with NSE. The category was

subscribed by 96.40 times i.e. for 3,93,32,000 Equity Shares. Total number of shares allotted in this category is 4,08,000 Equity Shares to 42 successful applicants. The category wise details of the Basis of Allotment are as under:

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPC	VC'S	TOTAL
ALLOTMENT	-	-	9,000	29,000	2,09,000	1,52,000	9,000	4,08,000

**5) Allocation to Market Maker:**

The Basis of Allotment to Market Maker who have bid at Issue Price of ₹ 128/- per Equity Shares or above, was finalized in consultation with NSE. The category was subscribed 1.00 times i.e. for 1,08,000 Equity Shares the total number of shares allotted in this category is 1,08,000 Equity Share. The category wise details of the Basis of Allotment are as under:

SR NO	CATEGORY	NO. OF APPLICATIONS RECEIVED	% OF TOTAL	TOTAL NO. OF EQUITY SHARES APPLIED	% TO TOTAL	NO. OF EQUITY SHARES ALLOTTED PER BIDDER	RATIO	TOTAL NO. OF EQUITY SHARES ALLOTTED
1	1,08,000	1	100.00	1,08,000	100.00	1,08,000	1:1	1,08,000
	<b>TOTAL</b>	<b>1</b>	<b>100.00</b>	<b>1,08,000</b>	<b>100.00</b>	<b>1,08,000</b>		<b>1,08,000</b>

**6) Allotment to Anchor Investors (After Technical Rejection)**

The Company in consultation with the BRLM has allocated 6,09,000 Equity Shares to 6 Anchor Investors at the Anchor Investor Issue Price of ₹ 128/- per Equity Shares in accordance with the SEBI ICDR Regulations. This represents 60% of the QIB Category.

CATEGORY	FIS/BANKS	MF'S	IC'S	NBFC'S	AIF	FPC	OTHERS	TOTAL
ALLOTMENT	-	-	-	79,000	4,45,000	85,000	-	6,09,000

The Board of Directors of our Company at its meeting held on November 12, 2025 has taken on record the basis of allotment of Equity Shares approved by the Designated Stock Exchange, being National Stock Exchange of India Limited and has allotted the Equity Shares to various successful applicants. The Allotment Advice Cum Refund Intimation will be dispatched to the address of the investors as registered with the depositories. Further, instructions to the SCSSBS have been dispatched/mailed for unblocking of funds and transfer to the Public Issue Account on or before November 13, 2025 and In case the same is not received within ten days, investors may contact the Registrar to the Issue at the address given below. The Equity Shares allotted to the successful allottees shall be uploaded on or before November 13, 2025 for credit into the respective beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is in the process of obtaining the listing and trading approval from National Stock Exchange of India Limited and the trading of the Equity Shares is expected to commence on November 14, 2025.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated November 11, 2025 ("Prospectus").

**NOTICE TO INVESTORS: CORRIGENDUM TO THE PROSPECTUS ("THE CORRIGENDUM")**

With reference to the Prospectus dated November 11, 2025, filed with the RoC and submitted to the Stock Exchange and SEBI, attention to the investors is drawn to the following:

In furtherance to the disclosure made in the Number of Locked in shares (XII) appearing under the heading "Table I - Summary Statement holding of specified securities" in the chapter titled "Capital Structure" on page no. 78 of the Prospectus shall stand replaced as below:

Category (I)	Category of shareholder (II)	Nos. of shareholders (III)	No. of fully paid up equity shares held (IV)	No. of Partly paid-up equity shares held (V)	No. of shares underlying Depository Receipts (VI)	Total nos. shares held (VII) = (IV) + (V) + (VI)	Shareholding as a % of total no. of shares (calculated as per SCRR, 1957) (VIII) As a % of (A+B+C2)	Number of Voting Fresh held in each class of securities (IX)			No of shares underlying Outstanding convertible securities (including Warrants) (X)	Shareholding, as a % assuming full convertible securities (as a percentage of diluted share capital) (XI) = (VII) + (X) As a % of (A+B+C2)	Number of Locked in shares (XII)		Number of Shares pledged or otherwise encumbered (XIII)		Number of equity shares held in dematerialized form (XIV)
								No of Voting (XIV) Rights		Total as a % of (A+B+C)			No (a)	As a % of total Shares held (b)	No (a)	As a % of total Shares held (b)	
								Class Equity	Class								
A	Promoters & Promoters Group	7	55,00,000	0	0	55,00,000	92.68	55,00,000	0	55,00,000	92.68	0	0	0	0	0	55,00,000
B	Public	29	4,34,434	0	0	4,34,434	7.32	4,34,434	0	4,34,434	7.32	4,34,434	7.32	0	0	0	4,34,434
C	Non Promoters Non-Public	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C1	Shares underlying DRs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C2	Shares held by Employee Trusts	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	<b>Total (A+B+C)</b>	<b>36</b>	<b>59,34,434</b>	<b>-</b>	<b>-</b>	<b>59,34,434</b>	<b>100.00</b>	<b>59,34,434</b>	<b>-</b>	<b>59,34,434</b>	<b>100.00</b>	<b>59,34,434</b>	<b>100.00</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>59,34,434</b>

The Prospectus shall be read in conjunction with this Corrigendum. The information in this Corrigendum supersedes the information provided in the Prospectus to the extent inconsistent with the information in the Prospectus. The Prospectus stands amended to the extent stated hereinabove. All capitalised terms used in this Corrigendum shall unless the context otherwise requires, have the same meanings as ascribed in the Prospectus.

**INVESTORS, PLEASE NOTE**

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, MUFG INTIME INDIA PRIVATE LIMITED (Formerly Link Intime India Private Limited) at [www.in.mpms.mufg.com](http://www.in.mpms.mufg.com)

All future correspondence in this regards may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodge and payment details at the address of the Registrar given below:



**MUFG INTIME INDIA PRIVATE LIMITED**  
(Formerly Link Intime India Private Limited)  
**Address:** C- 101, Embassy 247, L B S Marg, Vikhroli West, Mumbai -400083, Maharashtra;  
**Tel No.:** +91 810 811 4949  
**Email Id:** [curislifesciences.smeipo@in.mpms.mufg.com](mailto:curislifesciences.smeipo@in.mpms.mufg.com)  
**Investor Grievance Email:** [curislifesciences.smeipo@in.mpms.mufg.com](mailto:curislifesciences.smeipo@in.mpms.mufg.com)  
**Website:** [www.in.mpms.mufg.com](http://www.in.mpms.mufg.com) **Contact Person:** Ms. Shanti Gopalkrishnan;  
**SEBI Registration No.:** INR000004058; **CIN:** U67190MH1999PTC118368.

**Place:** Sanand, Gujarat  
**Date:** November 13, 2025

**THE LEVEL OF SUBSCRIPTION SHOULD NOT BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF CURIS LIFESCIENCES LIMITED**

Disclaimer: Curis Lifesciences Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Ahmedabad on November 11, 2025 and thereafter with SEBI and the Stock Exchanges. The Prospectus is available on the website of the SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), website of NSE Emerge at [https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#sme\\_offer](https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#sme_offer) and is available on the websites of the BRLM at [www.finaaxcapital.com](http://www.finaaxcapital.com). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the chapter titled "Risk Factors" beginning on page 25 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in 'offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

On behalf of Board of Directors  
**FOR, CURIS LIFESCIENCES LIMITED**  
Sd/-  
Nikhil Purohit  
Company Secretary & Compliance Officer